In 2023, the Korean market for digital therapeutics is expected to expand significantly, with 27 innovative medical devices receiving official government approval.

AimMed’s Somzz and Welt’s WELT-I are innovative medical devices designed to address insomnia, offering personalized recommendations, behavioral interventions, and sleep diary data to improve sleep efficiency and alleviate anxiety.

The third DTx device has not been approved since April, but the development pace has accelerated. The Ministry of Food and Drug Safety has authorized 47 clinical trials involving DTx devices, and six guidelines have been released for approving trial plans. The global market for DTx devices is promising due to increased demand for telemedicine, personalized healthcare, and real-time patient monitoring.